Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Opinion|Videos|April 10, 2025
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.
Advertisement
Advertisement
The 40th Annual European Association of Urology Congress in Madrid, Spain, featured an extensive scientific program. In a recent video for Urology Times®, Betty Wang, MD, provided insight on 3 presentations that she believes “may be game changing” in urology.
Related to this article
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.
Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.
Martin Schoen, MD, PhD, discusses how clinicians can interpret comparative real-world evidence and indirect analyses when head-to-head ARPI data are unavailable.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
A decision is expected by the fourth quarter of 2026.
Advertisement
Advertisement